Safety and Efficacy of THN102 in Patients With Parkinson's Disease and Excessive Daytime Sleepiness
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03624920 |
|
Recruitment Status :
Completed
First Posted : August 10, 2018
Results First Posted : December 1, 2020
Last Update Posted : December 1, 2020
|
Sponsor:
Theranexus
Information provided by (Responsible Party):
Theranexus
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Brief Summary:
This is a randomized, placebo-controlled, 3-way cross-over phase IIa trial comparing two dose levels of THN102 to placebo in patients suffering from Parkinson's disease associated with excessive daytime sleepiness.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Parkinson Disease | Drug: THN102 Dosage A Drug: THN102 Dosage B Drug: THN102 Dosage C | Phase 2 |
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 77 participants |
| Allocation: | Randomized |
| Intervention Model: | Crossover Assignment |
| Intervention Model Description: | Complete 3 way-Crossover |
| Masking: | Triple (Participant, Care Provider, Investigator) |
| Primary Purpose: | Treatment |
| Official Title: | Safety and Efficacy of THN102 in Patients With Parkinson's Disease and Excessive Daytime Sleepiness |
| Actual Study Start Date : | July 12, 2018 |
| Actual Primary Completion Date : | December 20, 2019 |
| Actual Study Completion Date : | February 24, 2020 |
Resource links provided by the National Library of Medicine
MedlinePlus Genetics related topics:
Parkinson disease
MedlinePlus related topics:
Parkinson's Disease
| Arm | Intervention/treatment |
|---|---|
|
Placebo Comparator: THN102 Dosage A
THN102 Dosage A is a Placebo
|
Drug: THN102 Dosage A
THN102 Dosages A: placebo
Other Name: Placebo |
|
Experimental: THN102 Dosage B
THN102 Dosage B : 200 mg/2 mg THN102 is a combination of modafinil 100mg and flecainide 1 mg daily dosage is 200 mg of modafinil and 2 mg of flecainide
|
Drug: THN102 Dosage B
THN102 Dosage B : 200mg/2mg
Other Name: Dosage B |
|
Experimental: THN102 Dosage C
THN102 Dosage C : 200 mg/18 mg THN102 is a combination of modafinil 100mg and flecainide 9 mg daily dosage is 200 mg of modafinil and 18 mg of flecainide
|
Drug: THN102 Dosage C
THN102 Dosage C: 200mg/18mg
Other Name: Dosage C |
Primary Outcome Measures :
- Safety Adverse Events [ Time Frame: 2 weeks ]Number of participants with spontaneously reported treatment-related adverse events
Secondary Outcome Measures :
- Epworth Sleeping Scale (ESS) [ Time Frame: 2 weeks ]Range of the scale : 0 to 24. A low score indicates a good outcome. Results shown are corresponding to a change from baseline of the ESS score.
- Psychomotor Vigilance Test (PVT) : Reaction Time (Miliseconds) Change From Baseline [ Time Frame: 2 weeks ]PVT measures reaction time in milliseconds. The results below are corresponding to the reaction time change from baseline.
- Montreal Cognitive Assessment Battery (MoCA) [ Time Frame: 2 weeks ]
MoCA score reflects the cognitive capacities of a person. Range of the total score of 10 test items: 0 to 30 points. A high score indicates good cognitive functioning. A score of 26 and above is considered normal.
The results below are shown as change from baseline of the MoCA score.
- Efficacy in Improving Sleepiness (ESS). Responders Rate, Change From Baseline [ Time Frame: 2 weeks ]ESS score responder rate, defined as the proportion of subjects with at least 25% ESS improvement from baseline, at the end of each treatment period
- Efficacy in Improving Sleepiness (ESS). Patients in Remission, Change From Baseline [ Time Frame: 2 weeks ]Number of patients in remission (=without residual sleepiness), i.e. ESS < 11 at the end of each treatment period
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years to 80 Years (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Subjects with a diagnosis of idiopathic Parkinson's disease as defined by the Movement Disorders Society (MDS).
- Subjects with Hoehn and Yahr scale score ≤ 4.
- Body mass index > 18 kg/m2 and < 35 kg/m2.
- Subjects should have a complaint of daytime sleepiness impacting their quality of life and/or daytime functioning (e.g. falling asleep while reading or watching television, while eating or talking with other people).
- Epworth Sleepiness Scale (ESS) score ≥ 14.
Exclusion Criteria:
- Subjects with known or with a suspected sleep apnea syndrome or who have any other cause of excessive daytime sleepiness, such as shift work sleep disorder.
- Psychiatric and neurological disorders (other than Parkinson's disease),
- Cardiovascular disorders such as - but not limited to
- Uncontrolled moderate to severe hypertension
- History or current diagnosis of electrocardiogram (ECG) abnormalities indicating significant risk of safety for patients participating in the study
- Recent myocardial infarction
- Stable or unstable angina pectoris
- Cardiac insufficiency or history of heart failure
- Previous history of cardiac valvular surgery
- Subjects with current impulse control disorder.
- Subjects showing dementia or with MoCA < 23.
- Subjects with current suicidal risk
- Current or recent (within one year) history of substance abuse or dependence disorder
- Other active clinically significant illness
- Subjects with hepatic or renal impairment
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03624920
Locations
Show 34 study locations
Sponsors and Collaborators
Theranexus
Investigators
| Study Chair: | Jean-Christophe Corvol, Prof | Hôpital La Pitié-Salpêtrière, 75651 Paris, France, Tel. +33 1 42 16 57 66, mail: jean-christophe.corvol@aphp.fr |
Study Documents (Full-Text)
Documents provided by Theranexus:
Documents provided by Theranexus:
Study Protocol [PDF] February 27, 2019
Statistical Analysis Plan [PDF] February 21, 2020
| Responsible Party: | Theranexus |
| ClinicalTrials.gov Identifier: | NCT03624920 |
| Other Study ID Numbers: |
THN102-202 |
| First Posted: | August 10, 2018 Key Record Dates |
| Results First Posted: | December 1, 2020 |
| Last Update Posted: | December 1, 2020 |
| Last Verified: | October 2020 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
| Studies a U.S. FDA-regulated Drug Product: | Yes |
| Studies a U.S. FDA-regulated Device Product: | No |
Additional relevant MeSH terms:
|
Parkinson Disease Disorders of Excessive Somnolence Sleepiness Parkinsonian Disorders Basal Ganglia Diseases Brain Diseases Central Nervous System Diseases Nervous System Diseases |
Movement Disorders Synucleinopathies Neurodegenerative Diseases Sleep Disorders, Intrinsic Dyssomnias Sleep Wake Disorders Mental Disorders |